Cargando…

Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer

BACKGROUND AND OBJECTIVES: Patients with muscle-invasive bladder cancer (MIBC) often experience a waiting period before radical surgery for numerous reasons; however, the COVID-19 outbreak has exacerbated this problem. Therefore, it is necessary to discuss the impact of the unavoidable time of surgi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuaishuai, Chen, Rui, Raj, Ashok, Xue, Ning, Zhao, Fangzheng, Shen, Xihao, Peng, Yunpeng, Zhu, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773555/
https://www.ncbi.nlm.nih.gov/pubmed/36568226
http://dx.doi.org/10.3389/fonc.2022.1001843
_version_ 1784855216778117120
author Li, Shuaishuai
Chen, Rui
Raj, Ashok
Xue, Ning
Zhao, Fangzheng
Shen, Xihao
Peng, Yunpeng
Zhu, Haitao
author_facet Li, Shuaishuai
Chen, Rui
Raj, Ashok
Xue, Ning
Zhao, Fangzheng
Shen, Xihao
Peng, Yunpeng
Zhu, Haitao
author_sort Li, Shuaishuai
collection PubMed
description BACKGROUND AND OBJECTIVES: Patients with muscle-invasive bladder cancer (MIBC) often experience a waiting period before radical surgery for numerous reasons; however, the COVID-19 outbreak has exacerbated this problem. Therefore, it is necessary to discuss the impact of the unavoidable time of surgical delay on the outcome of patients with MIBC. METHODS: In all, 165 patients from high-volume centers with pT2-pT3 MIBC, who underwent radical surgery between January 2008 and November 2020, were retrospectively evaluated. Patients’ demographic and pathological information was recorded. Based on the time of surgical delay endured, patients were divided into three groups: long waiting time (> 90 days), intermediate waiting time (30–90 days), and short waiting time (≤ 30 days). Finally, each group’s pathological characteristics and survival rates were compared. RESULTS: The median time of surgical delay for all patients was 33 days (interquartile range, IQR: 16–67 days). Among the 165 patients, 32 (19.4%) were classified into the long waiting time group, 55 (33.3%) into the intermediate waiting time group, and 78 (47.3%) into the short waiting time group. The median follow-up period for all patients was 48 months (IQR: 23–84 months). The median times of surgical delay in the long, intermediate, and short waiting time groups were 188 days (IQR: 98–367 days), 39 days (IQR: 35–65 days), and 16 days (IQR: 12–22 days), respectively. The 5-year overall survival (OS) rate for all patients was 58.4%, and that in the long, intermediate, and short waiting time groups were 35.7%, 61.3%, and 64.1%, respectively (P = 0.035). The 5-year cancer-specific survival (CSS) rates in the long, intermediate, and short waiting time groups were 38.9%, 61.5%, and 65.0%, respectively (P = 0.042). The multivariate Cox regression analysis identified age, time of surgical delay, pT stage, and lymph node involvement as independent determinants of OS and CSS. CONCLUSION: In patients with pT2-pT3 MIBC, the time of surgical delay > 90 days can have a negative impact on survival.
format Online
Article
Text
id pubmed-9773555
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97735552022-12-23 Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer Li, Shuaishuai Chen, Rui Raj, Ashok Xue, Ning Zhao, Fangzheng Shen, Xihao Peng, Yunpeng Zhu, Haitao Front Oncol Oncology BACKGROUND AND OBJECTIVES: Patients with muscle-invasive bladder cancer (MIBC) often experience a waiting period before radical surgery for numerous reasons; however, the COVID-19 outbreak has exacerbated this problem. Therefore, it is necessary to discuss the impact of the unavoidable time of surgical delay on the outcome of patients with MIBC. METHODS: In all, 165 patients from high-volume centers with pT2-pT3 MIBC, who underwent radical surgery between January 2008 and November 2020, were retrospectively evaluated. Patients’ demographic and pathological information was recorded. Based on the time of surgical delay endured, patients were divided into three groups: long waiting time (> 90 days), intermediate waiting time (30–90 days), and short waiting time (≤ 30 days). Finally, each group’s pathological characteristics and survival rates were compared. RESULTS: The median time of surgical delay for all patients was 33 days (interquartile range, IQR: 16–67 days). Among the 165 patients, 32 (19.4%) were classified into the long waiting time group, 55 (33.3%) into the intermediate waiting time group, and 78 (47.3%) into the short waiting time group. The median follow-up period for all patients was 48 months (IQR: 23–84 months). The median times of surgical delay in the long, intermediate, and short waiting time groups were 188 days (IQR: 98–367 days), 39 days (IQR: 35–65 days), and 16 days (IQR: 12–22 days), respectively. The 5-year overall survival (OS) rate for all patients was 58.4%, and that in the long, intermediate, and short waiting time groups were 35.7%, 61.3%, and 64.1%, respectively (P = 0.035). The 5-year cancer-specific survival (CSS) rates in the long, intermediate, and short waiting time groups were 38.9%, 61.5%, and 65.0%, respectively (P = 0.042). The multivariate Cox regression analysis identified age, time of surgical delay, pT stage, and lymph node involvement as independent determinants of OS and CSS. CONCLUSION: In patients with pT2-pT3 MIBC, the time of surgical delay > 90 days can have a negative impact on survival. Frontiers Media S.A. 2022-12-08 /pmc/articles/PMC9773555/ /pubmed/36568226 http://dx.doi.org/10.3389/fonc.2022.1001843 Text en Copyright © 2022 Li, Chen, Raj, Xue, Zhao, Shen, Peng and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Shuaishuai
Chen, Rui
Raj, Ashok
Xue, Ning
Zhao, Fangzheng
Shen, Xihao
Peng, Yunpeng
Zhu, Haitao
Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer
title Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer
title_full Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer
title_fullStr Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer
title_full_unstemmed Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer
title_short Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer
title_sort impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773555/
https://www.ncbi.nlm.nih.gov/pubmed/36568226
http://dx.doi.org/10.3389/fonc.2022.1001843
work_keys_str_mv AT lishuaishuai impactofthetimeofsurgicaldelayonsurvivalinpatientswithmuscleinvasivebladdercancer
AT chenrui impactofthetimeofsurgicaldelayonsurvivalinpatientswithmuscleinvasivebladdercancer
AT rajashok impactofthetimeofsurgicaldelayonsurvivalinpatientswithmuscleinvasivebladdercancer
AT xuening impactofthetimeofsurgicaldelayonsurvivalinpatientswithmuscleinvasivebladdercancer
AT zhaofangzheng impactofthetimeofsurgicaldelayonsurvivalinpatientswithmuscleinvasivebladdercancer
AT shenxihao impactofthetimeofsurgicaldelayonsurvivalinpatientswithmuscleinvasivebladdercancer
AT pengyunpeng impactofthetimeofsurgicaldelayonsurvivalinpatientswithmuscleinvasivebladdercancer
AT zhuhaitao impactofthetimeofsurgicaldelayonsurvivalinpatientswithmuscleinvasivebladdercancer